

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeval Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.
Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440
Email ID: complianceofficer@concordbiotech.com

July 02, 2025

To The Manager, Listing Department National Stock Exchange of India Ltd. Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai -400 051 Symbol: CONCORDBIO	To General Manager, Listing Department BSE Limited Phiroze Jeejabhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960
---	---

Dear Sir/Ma'am,

Sub.: Intimation in terms of the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ("SEBI LODR Regulations") on behalf of Concord Biotech Limited ("Company")

We are pleased to inform the exchanges that M/s. Concord Biotech Limited has made an equity investment of USD 1,500 in Stellon Biotech Inc. This investment represents the subscription of 15 million equity shares at a price of USD 0.0001 per share resulting into 75% ownership in Stellon Biotech Inc to expand Company's business operations in USA.

Disclosure is given in terms of the above referred provisions of SEBI Regulations, read with circular dated November 11, 2024 issued by the Securities and Exchange Board of India, bearing ref. no. SEBI/HO/CFD/PoD2/CIR/P/0155 ("said SEBI Circular").

The requisite details of terms of the provisions of Regulation 30 read with Schedule III of the SEBI Regulations and the said SEBI circular, are included in Annexure A, as enclosed herewith.

This is for your information and records.

For Concord Biotech Limited

Hina Patel
Company Secretary and Compliance Officer
(ACS:56541)

Encl : As above

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.
Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440
Email ID: complianceofficer@concordbiotech.com

Annexure-A

Sr. No.	Particulars	Details
a)	Name of the target entity, details in brief such as size, turnover etc.	Stellon Biotech Inc, Incorporated under General Corporation Law of the State of Delaware Authorised Share Capital (as on July 01, 2025): 25,000,000 shares, priced at USD 0.0001 per share Issued share capital (as on July 01, 2025): Shares of 5,000,000 at per share price of USD 0.0001 Net-worth (as on July 01, 2025): USD 500 (Stellon is following Calendar Year) Stellon Biotech Inc. is a Delaware-incorporated pharmaceutical company established in December 2024. As a newly formed entity, Stellon is currently in its pre-revenue phase and was specifically created to support the marketing and commercialization of products developed by Concord Biotech Limited. Stellon Biotech, is responsible for engaging in the marketing, distribution, and commercialization of pharmaceutical and biotechnological products within approved territories, subject to applicable regulatory approvals. Stellon will manage all related operational functions including warehousing, inventory planning, order processing, invoicing, collections, government pricing and rebate administration, customer service, and returns. All activities will be conducted in compliance with applicable laws, industry standards, and current Good Manufacturing Practices (cGMP). Stellon may appoint or collaborate with affiliates or third-party subcontractors to execute these functions, while remaining accountable for their compliance with contractual and legal obligations.

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeval Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at arm's length	Stellon Biotech Inc will become subsidiary of Concord Biotech Limited. Therefore, the said investment would fall under the purview of Related Party Transaction. This investment and subscription of shares will be at arm's length basis. None of the promoter/ promoter group/ group companies have any interest in the entity
c)	Industry to which the entity being acquired belongs	Biopharmaceutical Industry
d)	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	With Objective to expand business operations in USA for Concord Biotech Limited, through its own subsidiary with a local partner in the United States of America (U.S.A). Company proposed to utilize this U.S. Subsidiary to distribute and sell its products in USA. For that, Concord is subscribing 15 million equity shares at USD 0.0001 each, aggregating to USD\$ 1500 resulting into 75% ownership in Stellon Biotech Inc.
e)	brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable
f)	indicative time period for completion of the acquisition	The equity shares against the current investment will be allotted within 90 days from the Investment.
g)	consideration - whether cash consideration or share swap or any other form and details of the same;	Cash Consideration
h)	cost of acquisition and/or the price at which the shares are acquired;	15 million equity shares of USD 0.0001 each, aggregating to USD 1500 in Stellon Biotech Inc
i)	percentage of shareholding / control acquired and / or number of shares acquired;	75% in the equity of Stellon Biotech Inc.

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeval Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	To engage in the marketing, distribution, and commercialization of pharmaceutical and biotechnological products within approved territories, subject to applicable regulatory approvals; to manage all related operational functions including warehousing, inventory planning, order processing, invoicing, collections, government pricing and rebate administration, customer service, and returns; to ensure all activities are conducted in compliance with applicable laws, industry standards, and good manufacturing practices (cGMP); to maintain accurate records of such operations; and to appoint or collaborate with affiliates or third-party subcontractors for the execution of these functions, while remaining responsible for their compliance with contractual and legal obligations. Brief Details of Stellon Biotech Inc are as under: <table><tr><th>Particulars</th><th>Details</th></tr><tr><td>Registration Number</td><td>20244546292</td></tr><tr><td>Date of Incorporation</td><td>December 19 ,2024</td></tr><tr><td>History of last 3 years' Turnover</td><td>Year 2024: Nil (Company is following calendar year)</td></tr><tr><td>Country of Presence</td><td>United states of America</td></tr></table>	Particulars	Details	Registration Number	20244546292	Date of Incorporation	December 19 ,2024	History of last 3 years' Turnover	Year 2024: Nil (Company is following calendar year)	Country of Presence	United states of America
Particulars	Details											
Registration Number	20244546292											
Date of Incorporation	December 19 ,2024											
History of last 3 years' Turnover	Year 2024: Nil (Company is following calendar year)											
Country of Presence	United states of America											